On Thursday, Moderna's shares fell sharply after partial data regarding its cancer vaccine, developed in collaboration with Merck, was leaked.
This leak caused investor concern, leading to a drop in the stock price, even though the complete data released later indicated that the personalized vaccine, intismeran autogene, when combined with Merck's Keytruda, showed a 42% reduction in the risk of recurrence or death in specific melanoma patients compared to Keytruda alone.
The full results were anticipated to be presented at the European Society for Medical Oncology conference over the weekend, highlighting the importance of this data for both companies and the broader oncology market. The situation remains fluid, and further updates are expected as more information becomes available